Patents by Inventor Gary H. Posner
Gary H. Posner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190060456Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: October 25, 2018Publication date: February 28, 2019Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Publication number: 20180117156Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: October 2, 2017Publication date: May 3, 2018Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Patent number: 9775903Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: GrantFiled: January 13, 2011Date of Patent: October 3, 2017Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Publication number: 20170114013Abstract: The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.Type: ApplicationFiled: October 31, 2016Publication date: April 27, 2017Inventors: Gary H. Posner, Kimberly S. Petersen, Lindsey C. Hess, Douglas T. Genna, Scott Borella
-
Patent number: 9611273Abstract: Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: GrantFiled: February 28, 2013Date of Patent: April 4, 2017Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Alexander M. Jacobine, Rachel D. Slack, Jennifer R. Mazzone
-
Patent number: 9493480Abstract: Anilide derivatives of the natural trioxane artemisinin were prepared and evaluated for antimalarial efficacy in Plasmodium berghei-infected mice. Selected anilides derivatives administered orally as one single-digit dose combined with mefloquine hydrochloride were completely curative, i.e., all 5 of the mice in the particular treatment group had no detectable parasitemia on day 30 post infection, gained as much weight by day 30 post infection as the control mice (no infection), and behaved normally.Type: GrantFiled: April 16, 2012Date of Patent: November 15, 2016Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Rachel D. Slack
-
Patent number: 9487538Abstract: Two-carbon linked artemisinin-derived trioxane dimers and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: GrantFiled: January 22, 2014Date of Patent: November 8, 2016Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Bryan T. Mott
-
Patent number: 9481646Abstract: The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.Type: GrantFiled: April 18, 2008Date of Patent: November 1, 2016Assignee: The Johns Hopkins UniversityInventors: Gary H. Posner, Kimberly S. Petersen, Lindsey C. Hess, Douglas T. Genna, Scott Borella
-
Publication number: 20150361088Abstract: Two-carbon linked artemisinin-derived trioxane dimers and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: ApplicationFiled: January 22, 2014Publication date: December 17, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: GARY H. POSNER, BRYAN T. MOTT
-
Publication number: 20150183798Abstract: Anilide derivatives of the natural trioxane artemisinin were prepared and evaluated for antimalarial efficacy in Plasmodium berghei-infected mice. Selected anilides derivatives administered orally as one single-digit dose combined with mefloquine hydrochloride were completely curative, i.e., all 5 of the mice in the particular treatment group had no detectable parasitemia on day 30 post infection, gained as much weight by day 30 post infection as the control mice (no infection), and behaved normally.Type: ApplicationFiled: April 16, 2012Publication date: July 2, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Rachel D. Slack
-
Publication number: 20150031677Abstract: Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: ApplicationFiled: February 28, 2013Publication date: January 29, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Alexander M. Jacobine, Rachel D. Slack, Jennifer R. Mazzone
-
Patent number: 8906888Abstract: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: April 25, 2006Date of Patent: December 9, 2014Assignees: Cytochroma Inc., Johns Hopkins UniversityInventors: Uttam Saha, Gary H. Posner, Mehmet Kahraman
-
Patent number: 8884032Abstract: Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: GrantFiled: May 19, 2010Date of Patent: November 11, 2014Assignee: The Johns Hopkins UniversityInventors: Gary H. Posner, Lauren E. Woodard, David R. Levine, Deuk Kyu Moon, Bryan T. Mott
-
Patent number: 8592611Abstract: The disclosure provides novel trioxane sulfur dimers having Formula I: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer, proliferative disorders, and/or malaria using these compounds and/or compositions.Type: GrantFiled: July 17, 2009Date of Patent: November 26, 2013Assignee: The Johns Hopkins UniversityInventors: Gary H. Posner, Andrew S. Rosenthal
-
Publication number: 20130157987Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: January 13, 2011Publication date: June 20, 2013Applicants: JOHNS HOPKINS UNIVERSITY, CYTOCHROMA INC.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Patent number: 8431611Abstract: This disclosure provides improved derivatives of artemisinin; pharmaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.Type: GrantFiled: October 19, 2007Date of Patent: April 30, 2013Assignee: Johns Hopkins UniversityInventors: Lorraine V. Brando, Gary H. Posner, John G. D'Angelo, Robert H. Yolken, Christopher P. Hencken, Lauren Woodard
-
Publication number: 20120108545Abstract: Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: ApplicationFiled: May 19, 2010Publication date: May 3, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Lauren E. Woodard, David R. Levine, Deuk Kyu Moon, Bryan T. Mott
-
Patent number: 8106035Abstract: The present invention provides novel D-ring and side-chain analogs of 1?,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: December 18, 2003Date of Patent: January 31, 2012Assignee: Cytochroma Inc.Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Hong Woon Yang, Steven M. Silverman, Byung-Chul Suh, Jay A. White, Glenville Jones, Uttam Saha, Heung Bae Jeon
-
Publication number: 20110124603Abstract: The disclosure provides novel trioxane sulfur dimers having Formula I: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer, proliferative disorders, and/or malaria using these compounds and/or compositions.Type: ApplicationFiled: July 17, 2009Publication date: May 26, 2011Inventors: Gary H. Posner, Andrew S. Rosenthal
-
Publication number: 20100137262Abstract: The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.Type: ApplicationFiled: April 18, 2008Publication date: June 3, 2010Inventors: Gary H. Posner, Kimberly S. Petersen, Lindsey C. Hess, Douglas T. Genna, Scott Borella